Sera Prognostics, Inc.

Good afternoon and welcome to the SARA prognostics conference call to review first quarter fiscal year 2025 results. At this time, all participants are in listen only mode. We will be facilitating a question and answer session toward the end of today's call. As a reminder, this call is being recorded for replay purposes. I would now like to turn the call over to Peter DiNardo of Capcom Partners for a few introductory comments.

Thank you, Andrew. Good afternoon, everyone. Welcome to Sarah Prognostics' first quarter fiscal year 2025 earnings conference call. At the close of the market today, Sarah Prognostics released its financial results for the quarter ended March 31, 2025. Presenting for the company today will be Zhenya Lingard, President and CEO, and Austin Erick, our CFO. During the call, we will review the financial results we released today, after which we will host a question and answer session. If you've not had a chance to review our quarterly earnings release, it can be found on our website at serra.com. This call can be heard live via webcast at serra.com, and a recording will be archived in the investor section of our website. Please note that some of the information presented today may contain projections or other forelooking statements about events and circumstances that have not yet occurred, including plans of projections for our business, future financial results, and market trends and opportunities. These statements are based on management's current expectations, and the actual events or results may differ materially and adversely from these expectations for a variety of reasons. We refer you to the documents the company files from time to time with the Securities and Exchange Commission, specifically the company's annual report on Form 10-K, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. These documents identify important risk factors that could cause the actual results to differ materially from those contained in our projections and other forward-looking statements. As a reminder, a webcast replay of this call will be available in the Investors section of our website. I will now turn the call over to Zhenya, Terra Prognostics President and CEO. Zhenya?

Thank you, Peter, and good afternoon, everyone. It's been just a few short weeks since we last held our quarterly earnings call near the end of March, during which we shared a lot of updates regarding prime and commercial priorities. So I'll aim to keep my comments brief today. We've continued to make progress in driving the transition from our clinical evidence development phase with the full pivotal prime study results being communicated in January towards our next phase to pursue commercial growth opportunities. We are progressing nicely towards publication of the prime study results in a peer-reviewed journal. Today, I'll lay out our commercial roadmap over the next few quarters, which follows a geographically-focused ecosystem playbook with three primary components, which we will look to perfect first in about half a dozen states and nationally from there. First component is reimbursement. With a balanced approach towards commercial insurers, employers, and Medicaid, which is a key payer for most physicians with about 43% of all births in the United States paid for by Medicaid programs.